Investment analysts at Piper Jaffray Cos. assumed coverage on shares of Nektar Therapeutics (NASDAQ:NKTR) in a note issued to investors on Tuesday, AmericanBankingNews.com reports. The firm set an “overweight” rating on the stock. A number of other analysts have also recently weighed in on NKTR. Analysts at JPMorgan Chase & Co. cut their price target […]
Piper Jaffray Cos. Initiates Coverage on Nektar Therapeutics (NKTR) is a post from: Zolmax
The post Piper Jaffray Cos. Initiates Coverage on Nektar Therapeutics (NKTR) appeared first on Zolmax.